Rami Manochakian, Associate Professor and Thoracic Medical Oncologist at Mayo Clinic, shared a post on X:
“Hot off the press.
FDA just approved: Sevabertinib For patients with advanced HER2 mutant Non-Small Cell LungCancer who received prior systemic therapy. Approval is based on Results of SOHO-01 Phase 1/2 Trial.
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer.”
